Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1489
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 49–60 of 1,489 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Phase 2 Interventional

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

NCT07703436
Site status not listed — check the official record
View directory record Official record
Conditions
Grade 2 IDH1-mutant Glioma, Grade 3 IDH1-mutant Glioma, Glioma, IDH1-mutant Glioma, Oligodendroglioma, Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted, Astrocytoma IDH Mutant Grade 3, Astrocytoma IDH Mutant Grade 2
Interventions
Safusidenib
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

NCT07644559
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
Interventions
VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
25
States / cities
Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801
Status at this site: Recruiting
View directory record Official record
Conditions
Crohn's Disease
Interventions
IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
87
States / cities
Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Not applicable Interventional

Testing the mHealth App Intervention for Nondaily Smokers "SiS4"

NCT06678243
Status at this site: Recruiting
View directory record Official record
Conditions
Smoking Cessation
Interventions
Smiling instead of Smoking, QuitGuide
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Not yet recruiting Not applicable Interventional

Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study

NCT07596914
Site status not listed — check the official record
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia
Behavioral · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Not yet recruiting No phase listed Observational

A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

NCT07569367
Site status not listed — check the official record
View directory record Official record
Conditions
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Degeneration, Corticobasal Syndrome (CBS)
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Lutherville, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Phase 2 Interventional

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

NCT06123338
Status at this site: Recruiting
View directory record Official record
Conditions
Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
Interventions
Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine, 5-Fluorouracil, Docetaxel, Nutrition questionnaires (optional), stool and saliva samples (optional)
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Not applicable Interventional

The ArtixASCEND Study

NCT07135895
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Lower Limb Arterial Occlusion
Interventions
Artix Thrombectomy System
Device
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
23
States / cities
San Francisco, California • New Haven, Connecticut • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
64
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting No phase listed Observational

Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)

NCT06297993
Status at this site: Recruiting
View directory record Official record
Conditions
PSC
Interventions
Not listed
Lead sponsor
PSC Partners Seeking a Cure
Other
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

OCT Vibrography for Biomechanical Properties of Tissues

NCT05759780
Status at this site: Recruiting
View directory record Official record
Conditions
Cornea, Skin Diseases, Gingival Diseases
Interventions
Optical imaging of the tissues
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172
Site status not listed — check the official record
View directory record Official record
Conditions
Intracranial Arteriosclerosis, Stroke
Interventions
Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
114
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 7:24 AM EDT

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.